SCHEMBL16201694

SCHEMBL16201694

Cc1cc(S(=O)(=O)c2ccc(O)c(C)c2C)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.55
ALDH1A1 P00352 1/20 0.55
PKM P14618 1/20 0.55
ATM Q13315 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
ESR1 P03372 7/20 0.42
MAPT P10636 1/20 0.42
PABPC1 P11940 1/20 0.40
ERAP1 Q9NZ08 1/20 0.40
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39
RPS6KA3 P51812 1/20 0.39
ESR2 Q92731 1/20 0.39
COMT P21964 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13695492 0.88 GAA (0.54) GAAALDH1A1PKMATMMEN1
SCHEMBL69907 0.83 GAA (0.58) GAAALDH1A1PKMESR1MAPT
SCHEMBL29599083 0.83 GAA (0.58) GAAALDH1A1PKMESR1MAPT
SCHEMBL29381371 0.82 GAA (0.50) GAAALDH1A1PKMATMMEN1
SCHEMBL14855745 0.81 GAA (0.67) GAAALDH1A1PKMATMMEN1
SCHEMBL9340571 0.81 GAA (0.42) GAAALDH1A1PKMATMMEN1
SCHEMBL5155634 0.81 GAA (0.42) GAAALDH1A1PKMATMMEN1
SCHEMBL29599468 0.81 GAA (0.42) GAAALDH1A1PKMATMMEN1
SCHEMBL23182558 0.79 TP53 (0.44) GAAALDH1A1PKMATMMEN1
SCHEMBL10497950 0.79 CA12 (0.47) GAAALDH1A1PKMATMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340505-B2 Type III secretion inhibitors, analogs and uses thereof UNIVERSITY OF MASSACHUSETTS (US) 2016-05-17 US disclosed
US-9340505-B2 Type III secretion inhibitors, analogs and uses thereof UNIVERSITY OF MASSACHUSETTS (US) 2016-05-17 US disclosed
US-20140323483-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF UNIVERSITY OF MASSACHUSETTS (US) 2014-10-30 US disclosed
US-20140323483-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF UNIVERSITY OF MASSACHUSETTS (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323483-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF GBA3, CLPP, PEX3 GAA 140/4885ALDH1A1 4877/4885PKM 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.